The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine

Brain, Behavior, and Immunity

Volumn 51, Issue , 2016, Pages 99-108

  Frank, Matthew G ^a   Adhikary, Sweta ^b   Sobesky, Julia L ^a   Weber, Michael D ^a   Watkins, Linda R ^a   Maier, Steven F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

DAMP; HMGB1; Methamphetamine; Microglia; Neuroinflammation; Neurotoxicity

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; METHAMPHETAMINE; AUTACOID; HBP1 PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; SPRAGUE DAWLEY RAT; VENTRAL TEGMENTUM; ANIMAL; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALITIS; METABOLISM;

ANIMALS; BRAIN; CORPUS STRIATUM; ENCEPHALITIS; HMGB1 PROTEIN; INFLAMMATION MEDIATORS; MALE; METHAMPHETAMINE; MICROGLIA; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; VENTRAL TEGMENTAL AREA;

EID: 84938702437     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.08.001     Document Type: Article

References (50)

1. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997), 3389–3402.
2. Antoine, D.J., Harris, H.E., Andersson, U., Tracey, K.J., Bianchi, M.E., A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol. Med. 20 (2014), 135–137.
3. Bianchi, M.E., Manfredi, A.A., High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220 (2007), 35–46.
4. Bowyer, J.F., Ali, S., High doses of methamphetamine that cause disruption of the blood–brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60 (2006), 521–532.
5. Buchanan, J.B., Sparkman, N.L., Johnson, R.W., A neurotoxic regimen of methamphetamine exacerbates the febrile and neuroinflammatory response to a subsequent peripheral immune stimulus. J. Neuroinflammation, 7, 2010, 82.
6. Cadet, J.L., Krasnova, I.N., Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 88 (2009), 101–119.
7. Chomczynski, P., Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal. Biochem. 162 (1987), 156–159.
8. Coelho-Santos, V., Goncalves, J., Fontes-Ribeiro, C., Silva, A.P., Prevention of methamphetamine-induced microglial cell death by TNF-alpha and IL-6 through activation of the JAK-STAT pathway. J. Neuroinflammation, 9, 2012, 103.
9. Coutinho, A., Flynn, C., Burdo, T.H., Mervis, R.F., Fox, H.S., Chronic methamphetamine induces structural changes in frontal cortex neurons and upregulates type I interferons. J. Neuroimmune Pharmacol. 3 (2008), 241–245.
10. Escubedo, E., Guitart, L., Sureda, F.X., Jimenez, A., Pubill, D., Pallas, M., Camins, A., Camarasa, J., Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814 (1998), 120–126.
11. Fantegrossi, W.E., Ciullo, J.R., Wakabayashi, K.T., De La Garza, R. 2nd, Traynor, J.R., Woods, J.H., A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151 (2008), 533–543.
12. Flora, G., Lee, Y.W., Nath, A., Maragos, W., Hennig, B., Toborek, M., Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromol. Med. 2 (2002), 71–85.
13. Flora, G., Lee, Y.W., Nath, A., Hennig, B., Maragos, W., Toborek, M., Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 179 (2003), 60–70.
14. Frank, M.G., Wieseler-Frank, J.L., Watkins, L.R., Maier, S.F., Rapid isolation of highly enriched and quiescent microglia from adult rat hippocampus: immunophenotypic and functional characteristics. J. Neurosci. Methods 151 (2006), 121–130.
15. Frank, M.G., Weber, M.D., Watkins, L.R., Maier, S.F., Stress sounds the alarmin. The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. Brain Behav. Immun. 48 (2015), 1–7.
16. Gerlitz, G., Hock, R., Ueda, T., Bustin, M., The dynamics of HMG protein-chromatin interactions in living cells. Biochem. Cell Bio. = Biochim. Biol. Cell. 87 (2009), 127–137.
17. Goncalves, J., Baptista, S., Martins, T., Milhazes, N., Borges, F., Ribeiro, C.F., Malva, J.O., Silva, A.P., Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur. J. Neurosci. 31 (2010), 315–326.
18. Guilarte, T.R., Nihei, M.K., McGlothan, J.L., Howard, A.S., Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122 (2003), 499–513.
19. Hreggvidsdottir, H.S., Ostberg, T., Wahamaa, H., Schierbeck, H., Aveberger, A.C., Klevenvall, L., Palmblad, K., Ottosson, L., Andersson, U., Harris, H.E., The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86 (2009), 655–662.
20. Imam, S.Z., Ali, S.F., Aging increases the susceptiblity to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J. Neurochem. 78 (2001), 952–959.
21. Kelly, K.A., Miller, D.B., Bowyer, J.F., O'Callaghan, J.P., Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. J. Neurochem. 122 (2012), 995–1009.
22. Krasnova, I.N., Cadet, J.L., Methamphetamine toxicity and messengers of death. Brain Res. Rev. 60 (2009), 379–407.
23. Ladenheim, B., Krasnova, I.N., Deng, X., Oyler, J.M., Polettini, A., Moran, T.H., Huestis, M.A., Cadet, J.L., Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol. Pharmacol. 58 (2000), 1247–1256.
24. Lai, Y.T., Tsai, Y.P., Cherng, C.G., Ke, J.J., Ho, M.C., Tsai, C.W., Yu, L., Lipopolysaccharide mitigates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression. J. Neural. Transm. 116 (2009), 405–415.
25. Lamkanfi, M., Sarkar, A., Vande Walle, L., Vitari, A.C., Amer, A.O., Wewers, M.D., Tracey, K.J., Kanneganti, T.D., Dixit, V.M., Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185 (2010), 4385–4392.
26. LaVoie, M.J., Card, J.P., Hastings, T.G., Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 187 (2004), 47–57.
27. Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A.M., Rossetti, C., Molteni, M., Casalgrandi, M., Manfredi, A.A., Bianchi, M.E., Vezzani, A., Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16 (2010), 413–419.
28. Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M.H., Seto, A., Yoshimura, M., Kitaichi, K., Hasegawa, T., Saito, K., Yamada, Y., Seishima, M., Sekikawa, K., Kim, H.C., Nabeshima, T., Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J. Neurosci. 24 (2004), 2212–2225.
29. Proescholdt, M.G., Hutto, B., Brady, L.S., Herkenham, M., Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neuroscience 95 (2000), 577–592.
30. Pubill, D., Canudas, A.M., Pallas, M., Camins, A., Camarasa, J., Escubedo, E., Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003), 490–499.
31. Ransohoff, R.M., Perry, V.H., Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27 (2009), 119–145.
32. Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K.J., Suda, S., Suzuki, K., Kawai, M., Takebayashi, K., Yamamoto, S., Matsuzaki, H., Ueki, T., Mori, N., Gold, M.S., Cadet, J.L., Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28 (2008), 5756–5761.
33. Sha, Y., Zmijewski, J., Xu, Z., Abraham, E., HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180 (2008), 2531–2537.
34. Sharma, H.S., Kiyatkin, E.A., Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J. Chem. Neuroanat. 37 (2009), 18–32.
35. Sriram, K., Miller, D.B., O'Callaghan, J.P., Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96 (2006), 706–718.
36. Sun, S.C., Ganchi, P.A., Ballard, D.W., Greene, W.C., NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259 (1993), 1912–1915.
37. Theodore, S., Stolberg, S., Cass, W.A., Maragos, W.F., Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann. N. Y. Acad. Sci. 1074 (2006), 178–190.
38. Thomas, D.M., Kuhn, D.M., Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J. Neurochem. 92 (2005), 790–797.
39. Thomas, D.M., Dowgiert, J., Geddes, T.J., Francescutti-Verbeem, D., Liu, X., Kuhn, D.M., Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367 (2004), 349–354.
40. Thomas, D.M., Francescutti-Verbeem, D.M., Kuhn, D.M., Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. J. Neurochem. 106 (2008), 696–705.
41. Tocharus, J., Khonthun, C., Chongthammakun, S., Govitrapong, P., Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J. Pineal Res. 48 (2010), 347–352.
42. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D.J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., Shams, S.S., Yang, H., Varani, L., Andersson, U., Tracey, K.J., Bachi, A., Uguccioni, M., Bianchi, M.E., Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209 (2012), 1519–1528.
43. Wang, K.H., Penmatsa, A., Gouaux, E., Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature, 2015.
44. Weber, M.D., Frank, M.G., Tracey, K.J., Watkins, L.R., Maier, S.F., Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male sprague dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J. Neurosci. 35 (2015), 316–324.
45. Yamaguchi, T., Kuraishi, Y., Minami, M., Nakai, S., Hirai, Y., Satoh, M., Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. Neurosci. Lett. 128 (1991), 90–92.
46. Yamaguchi, T., Kuraishi, Y., Yabuuchi, K., Minami, M., Satoh, M., In situ hybridization analysis of the induction of interleukin-1 beta mRNA by methamphetamine in the rat hypothalamus. Mol. Cell. Neurosci. 2 (1991), 259–265.
47. Yang, H., Tracey, K.J., High mobility group box 1 (HMGB1). Crit. Care Med. 33 (2005), S472–S474.
48. Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H.E., Susarla, S.M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C.J., Wang, H., Roth, J., Warren, H.S., Fink, M.P., Fenton, M.J., Andersson, U., Tracey, K.J., Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101 (2004), 296–301.
49. Yang, H., Wang, H., Ju, Z., Ragab, A.A., Lundback, P., Long, W., Valdes-Ferrer, S.I., He, M., Pribis, J.P., Li, J., Lu, B., Gero, D., Szabo, C., Antoine, D.J., Harris, H.E., Golenbock, D.T., Meng, J., Roth, J., Chavan, S.S., Andersson, U., Billiar, T.R., Tracey, K.J., Al-Abed, Y., MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med. 212 (2015), 5–14.
50. Zou, J.Y., Crews, F.T., Release of neuronal HMGB1 by ethanol through decreased HDAC activity activates brain neuroimmune signaling. PLoS ONE, 9, 2014, e87915.